Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 891-900

  Beck, Raphaël ^a   Pedrosa, Rozangela Curi ^b   Dejeans, Nicolas ^a   Glorieux, Christophe ^a   Levêque, Philippe ^a   Gallez, Bernard ^a   Taper, Henryk ^a   Eeckhoudt, Stéphane ^c   Knoops, Laurent ^c,d   Calderon, Pedro Buc ^a,e   Verrax, Julien ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^e UNIVERSIDAD ARTURO PRAT   (Chile)

Author keywords

Ascorbate; Bcr Abl; Hsp90; Menadione; Oxidative stress; Redox cycling

Indexed keywords

ASCORBIC ACID; BCR ABL PROTEIN; HEAT SHOCK PROTEIN 90; IMATINIB; MENADIONE; REACTIVE OXYGEN METABOLITE; HYDROGEN PEROXIDE; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER TRANSPLANTATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; CELL PROTECTION; CELL STRAIN K 562; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ASCORBIC ACID; CELL DEATH; CELL LINE, TUMOR; CYTOPROTECTION; ERYTHROCYTES; FUSION PROTEINS, BCR-ABL; HUMANS; HYDROGEN PEROXIDE; K562 CELLS; MICE; MICE, NUDE; MUTANT PROTEINS; NEOPLASMS; OXIDATIVE STRESS; VITAMIN K 3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80555137586     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9441-3     Document Type: Article

References (33)

1. Behrend L, Henderson G, Zwacka RM (2003) Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 31(Pt 6):1441-1444
2. Wu WS (2006) The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25(4):695-705
3. Sun Y, Oberley LW, Elwell JH, Sierra-Rivera E (1989) Antioxidant enzyme activities in normal and transformed mouse liver cells. Int J Cancer 44(6):1028-1033
4. Verrax J, Cadrobbi J, Marques C, Taper H, Habraken Y, Piette J, Calderon PB (2004) Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis 9(2):223-233
5. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10(3):241-252
6. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88(3):1052-1061
7. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH (2003) Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 102(13):4512-4519
8. Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc CP (2003) The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 38(5):451-457
9. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc CP (2005) Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 39(6):649-657
10. Verrax J, Stockis J, Tison A, Taper HS, Calderon PB (2006) Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol 72(6):671-680
11. Verrax J, Vanbever S, Stockis J, Taper H, Buc Calderon P (2007) Role of glycolysis inhibition and poly (ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer 120(6):1192-1197
12. Dejeans N, Tajeddine N, Beck R, Verrax J, Taper H, Gailly P, Calderon PB (2010) Endoplasmic reticulum calcium release potentiates the ER stress and cell death caused by an oxidative stress in MCF-7 cells. Biochem Pharmacol 79(9):1221-1230
13. Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, Feron O, Calderon PB (2009) Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol 77(3):375-383
14. Verrax J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PB (2009) In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem 16(15):1821-1830
15. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944):824-830
16. Elefanty AG, Hariharan IK, Cory S (1990) bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9(4):1069-1078
17. Heisterkamp N, Jenster G, ten HJ, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344(6263):251-253
18. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 87(17):6649-6653
19. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247(4946):1079-1082
20. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561-566
21. Jiang X, Saw KM, Eaves A, Eaves C (2007) Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99(9):680-693
22. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117-125
23. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11(7):355-360
24. Baudhuin P, Beaufay H, Rahman-Li Y, Sellinger OZ, Wattiaux R, Jacques P, De DC (1964) Tissue fractionation studies. 17. Intracellular distribution of monoamine oxidase, aspartate aminotransferase, alanine aminotransferase, D-amino acid oxidase and catalase in rat-liver tissue. Biochem J 92(1):179-184
25. Ilaria RL Jr, Van Etten RA (1995) The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86(10):3897-3904
26. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ (2001) Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97(5):1404-1412
27. Toth KM, Clifford DP, Berger EM, White CW, Repine JE (1984) Intact human erythrocytes prevent hydrogen peroxide-mediated damage to isolated perfused rat lungs and cultured bovine pulmonary artery endothelial cells. J Clin Invest 74(1):292-295
28. Agar NS, Sadrzadeh SM, Hallaway PE, Eaton JW (1986) Erythrocyte catalase. A somatic oxidant defense? J Clin Invest 77(1):319-321
29. Winterbourn CC, Stern A (1987) Human red cells scavenge extracellular hydrogen peroxide and inhibit formation of hypochlorous acid and hydroxyl radical. J Clin Invest 80(5):1486-1491
30. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102(38):13604-13609
31. Beck R, Verrax J, Dejeans N, Taper H, Calderon PB (2009) Menadione Reduction by Pharmacological Doses of Ascorbate Induces an Oxidative Stress That Kills Breast Cancer Cells. Int J Toxicol 28(1):33-42
32. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591
33. Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11(12):3013-3069